This post hoc double-blind , placebo-controlled study of atomoxetine ( 40-120mg / day ) over 10 weeks in adults with ADHD at 45 Japanese , Korean , and Taiwanese study sites focused on patient data from Korea ( atomoxetine , n = 37 ; placebo , n = 37 ) .